RxDoctor Payments DataLook up a doctor →

Janay Kissinger

Nurse Practitioner · Kansas City, MONPI 1669525721

Payments from drug & device makers

$13,915in general payments, 2019–2025

Across 646 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Lilly USA, LLC$755
  • QOL Medical, LLC$732
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$13,61298%
  • Education$3032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,915 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$29,367
Medicare patients
192
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$122,809
Humira(Cf) PenAdalimumab12$96,389
LinzessLinaclotide52$45,764
OzempicSemaglutide35$37,054
Mesalamine18$13,498
JardianceEmpagliflozin26$13,493
ErythromycinErythromycin Base21$6,368
Ursodiol28$5,596
Lubiprostone32$5,246
Colestipol Hcl48$4,951
Famotidine170$3,705
Lactulose15$1,165
Omeprazole76$1,083
Tenofovir Disoproxil Fumarate12$946
Pantoprazole Sodium94$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,490$122,80929 claims
AbbVieLinzess$3,607$45,76452 claims
Novo NordiskOzempic$75$37,05435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →